



Sandra Milligan

Head of Research and Development

As the Head of Research & Development for Organon, Sandy Milligan, M.D., is leading the advancement of a differentiated portfolio of medicines and solutions to help women and all patients live a better and healthier every day. In her role, Sandy oversees the organization's scientific, medical and regulatory capabilities in support of its diverse portfolio and long-term vision.

Before joining Organon, Sandy served as Merck's Senior Vice President and Head of Global Regulatory Affairs and Clinical Safety. Previously, she served as Vice President of Product Development Regulatory for Genentech, and from 2002 to 2012, she was at Amgen Inc. in positions of increasing responsibility across legal and regulatory affairs functions. Sandy served in the U.S. Army Medical Corps from 1987 to 1994.

Sandy was on the board of directors of the Drug Information Association (DIA) from 2011 to 2017, including serving as chair, and is now a DIA fellow. With a deep commitment to fostering diverse leadership, Sandy has served as co-sponsor of the Merck Women's Leadership program. She received her medical degree from George Washington University School of Medicine, a J.D. from the Georgetown University Law Center and a Bachelor of Science degree in biology and a Bachelor of Arts degree in psychology from the University of California, Irvine.

About Organon Organon (NYSE: OGN) is a global healthcare company formed through a spin-off from Merck & Co., Inc., Rahway, NJ, USA (NYSE: MRK) to focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women's health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon's products produce strong cash flows that will support investments in innovation and future growth opportunities in women's health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets. Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,300 employees with headquarters located in Jersey City, New Jersey. For more information, visit <http://www.organon.com> and connect with us on LinkedIn and Instagram.